Characteristics of drug resistance of tumor plasmocytes in vitro in patients with multiple myeloma differently responsive to chemotherapy
Golenkov, A.K.; Trifonova, E.V.; Kataeva, E.V.; Kil'diushevskiĭ, A.V.; Lutskaia, T.D.; Zariad'eva, E.A.; Nazarova, I.N.; Lukashina, M.N.; Zabotina, T.N.; Mikhaĭlova, I.N.; Inshakov, A.N.; Logacheva, N.P.; Baryshnikov, A.Iu.
Terapevticheskii Arkhiv 72(8): 38-41
2000
ISSN/ISBN: 0040-3660 PMID: 11019426 Document Number: 518312
Aim: To determine sensitivity of tumor plasmocytes in vitro to cytostatic drugs (prednisolone, alkeran belustin, vincristine, rubomycin, doxorubicin, cytarabin, methotrexate, cysplatin, etoposide). Material and methods: The sensitivity was measured with DISC method in 12 patients with multiple myeloma (MM) in two groups: resistant and responsive to induction polychemotherapy (PCT). Results: The groups appeared significantly different by lowering of pathological paraprotein concentration (PIg): by 7.4+-2.5% and 32.5+-3.7%, respectively (p<0.05). The resistance to the drugs was higher in the resistant patients than in the responders (0.7+-0.28 versus 0.4+-0.02, p<0.05). PCT schemes of resistant patients contained 65.0+-2.3% of ineffective drugs. In the responders the percentage was 35.7+-5.3% (p<0.05). Conclusion: The relationship exists between resistance of tumor plasmocytes to drugs in vitro and clinical findings.